Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study

NCT00526136 is registered in ClinicalTrials.gov with Advanz Pharma as lead sponsor.

NCT NCT00526136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00526136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
Lead sponsor
Advanz Pharma
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
July 31, 2008
Enrollment
735 (actual)
Sites
152

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation